CA2214143A1 - Combination compositions containing benazepril or benazeprilat and valsartan - Google Patents

Combination compositions containing benazepril or benazeprilat and valsartan Download PDF

Info

Publication number
CA2214143A1
CA2214143A1 CA002214143A CA2214143A CA2214143A1 CA 2214143 A1 CA2214143 A1 CA 2214143A1 CA 002214143 A CA002214143 A CA 002214143A CA 2214143 A CA2214143 A CA 2214143A CA 2214143 A1 CA2214143 A1 CA 2214143A1
Authority
CA
Canada
Prior art keywords
active ingredient
valsartan
composition according
ingredient component
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002214143A
Other languages
French (fr)
Inventor
Marc De Gasparo
David Saul Cohen
Randy Lee Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2214143A1 publication Critical patent/CA2214143A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/556Angiotensin converting enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Abstract

The invention relates to pharmaceutical combination compositions for the treatment of hypertension, congestive heart failure and renal failure, comprising (1) the ACE-inhibitor benazepril of formula (I) or benazeprilat of formula (II) or a pharmaceutically acceptable salt thereof, and (2) the AT1antagonist valsartan of formula (III) or a pharmaceutically acceptable salt thereof, as weel as to methods for the treatment of hypertension, congestive heart failure and renal failure.

Description

COMBINATION ~OMPOSITIONS CONTAINING ~ENAZEPRIL OR BENAZEPRILAT AND VALSARTAN

There are dir~renL approaches for intervening regulatively at dirrers"l places in the renin-angiotensin cascade and for opening up possibilities to influence the regulation of blood pressure in dirrt ~t nL ways.

Any;olen~i"ogen, a c~2-macroglycoprotein, is split by the renin enzyme into the decapeptide any;otellsi" I which itself is biologically only very weakly active. The next step in the cascade is the removal of a further two amino acids by the action of the angiotensin-converting enzyme (ACE), bonded mainly in the endothelium, with rur",~lion of any;olensi,l ll. This latter is regarded as being one of the strongest natural vasoconstrictors.

The interruption of the enzymatic degradation of angiotensin I to angiotensin llwith so-called ACE-il ,hil,ilors is a sucessful variant for the regulation of blood pressure and thus also makes available a therapeutic method for the treatment ofcongestive heart failure.

One known representative from among the conventional ACE-inhibitors is the active ingredient 3-[(1 -(ethoxycarbonyl)-3-phenyl-(1 S)-propyl)amino]-2,3,4,5-tetra-hydro-2-oxo-1 H-1 -(3S)-ben,~epi"e-1 -acetic acid [ben~epril] of formula COOC2Hs ,HN

COOH

or (see EP 72352) (3S)-3-[[(1 S)-(1 -carboxy-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1 H-1 -benzazepine-1 -acetic acid [benazeprilat] of formula W O96/31234 PCT~EP96/01440 OOH
HN

COOH

(see EP 72352) and its pharmaceutically acceptable salts. Monohydrochloride merits special mention (benazepril hydrochloride).

The vasoconstrictive effects of angiotensin ll are produced by its action on thenon-striated muscle cells, the stimulation of the formation of the adrenergenic hormones epinephrine and norepinephrine as well as the increase of the activity of the sympathetic nervous system as a result of the formation of norepinephrine.
Angiotensin ll also has an influence on the electrolytic balance, produces e.g.
antinatriuretic and antidiuretic effects in the kidney and thereby promotes the release of, on the one hand, the vasopressin peptide from the pituitary gland and, on the other hand, of aldosterone from the adrenal glomerulosa. All these influences play an important part in the regulation of blood pressure.

Angiotensin ll interacts with specific receptors on the surface of the target cell. It has been possible to identify receptor subtypes which are termed e.g. AT1- and AT2-receptors. In recent times great efforts have been made to identify substances that bind to the AT~-receptor. Such active ingredients are often termed angiotensin ll antagonists. Because of the inhibition of the AT~-receptorsuch antagonists can be used e.g. as antihypertensives or for the treatment of congestive heart failure.

Angiotensin ll antagonists are therefore understood to be those active ingredients which bind to the AT~-receptor subtype. These include compounds having different structural features.

The representative selected for the AT~-antagonists is the active ingredient (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'(1 H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine [valsartan~ of formula W O96131234 PCTAEP~6G0144a CH~ ~ CH3 o CH

/ ~ / \ / \ COOH

HN
N=N

(see EP 443983) and its pharm~ceutic~lly acceptable salts.

Pharmaceutically acceptable salts of benazepril and valsartan are typically acidaddition salts. These acid addition salts are formed, for example, with strong i"Grganic acids, typically mineral acids, such as sulfuric acid, a phosphoric acid or a hydrohalic acid, with strong organic acids, typically with C~-C4alkanecarL,oxylic acids which may be substituted, e.g. by halogen, typically acetic acid, for example with dicarboxylic acids which may be unsaturated, such as oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, phthalic acid or ~:rephll ,alic acid, for e,~d",;-!e with hydroxycarboxylic acids, such as ascorbic acid, glycotic acid, lactic acid, malic acid, tartaric acid or citric acid, for example with amino acids, such as aspartic acid or glutaminic acid, or e.g. benzoic acid, or with organic sulfonicacids, for example with C1-C4alkane acid or arylsulfonic acid which may be substituted, e.g. by halogen, for example with methane- or p-toluenesulfonic acid.
Suitable salts with bases are typically metal salts, such as alkali metal salts or alkaline earth metal salts, typically sodium, potassium or magnesium salts, or salts with a"~monia or an organic amine, such as morpholine, thiomorpholine, pi-peridine, pyrrolidine, a mono-, di- or tri-lower alkylamine, typically ethylamine, tert-butylamine, diethylamine, diisopropylamine, triethylamine, tributylamine or dimethylpropylamine, or a mono-, di- or trihydroxy-lower alkylamine, typically mono-, di- or triethanolamine. Corresponding internal salts can also be used.

Many assays endeavour also to develop combinations of dirr~renl active ingredients for the treatment of, for example, hypertension and congestive heartfailure. The advantages of such combinations are held to be, for example, that in W O96/31234 PCT~EP96/01440 these combinations doses of the individual components are used which are markedly lower than the effective dose for the single component. If, for example, antihypertensives having dir~ enl mechanisms of action are used in such combinations, then an additive effect is usually expected. The aim is, however, to provide such combinations that have, on the one hand, synergistic effects and, on the other hand, prolonged duration of efficacy.

PCT application WO 94/28924 discloses the combination of an ACE-inhibitor with an angiotensin-ll antagonist. Clinical tests of the combination of enalapril (ACE-inhibilur) with losartan (AT1-antagonist) in the indicated doses did not result in any siylliricalll synergistic effect of lowered blood pressure at all compared with the lowered blood pressure achieved with enalapril, only an additive effect could beascertained. Furthermore, there is no indication in said patent application of any prolonged duration of action after treatment with a combination of losartan and enalapril. Hence it cannot be assumed per se that such a combination of a potent ACE-i"l ,il,ilor with an AT1-antagonist produces a synergistic lowering of the blood pressure in man. Accordingly, there can be no mention of class effect.Rather, the ~~isclosure of WO 94/28924 shows that the combined application of the two indicated active ingredients effects an increase of the renal blood flowrate instead. Azizi et al., Circulation 1995; 92:825-834, likewise found additive effects of combined ACE inhil,ilion and AT1 antagonism (combination of captopriland losartan) on blood pressure and that the duration of the mean blood pressurefall was not prolonged by the combination of captopril and losartan.

All the more surprising is the ex,ueri,,,ental finding that the combined ad",in;~lrdlion of the ACE-inhibitor bend~epril or a phar",aceutically acceptable salt thereof with the AT1-antagonist valsartan or a pharmaceutically acceptable salt thereof results not only a synergistic antihypertensive effect but that a surprising prolongation of efficacy is also observed.

The advantage of these unexpected effects is that the dosages need not only often be smaller but also less frequent. This is in accordance with the desires and requirements of the patients to be treated.

In addition, any occurrence of side-effects can thus be minimised in some patients.

The combined blocking of the angiotensin-converting enzyme and the AT1-receptor also markedly reduces the increased circulation of vasocon~;Lri.;Li~/e angiotensin ll in a favourable manner.

Synergistic effect will be understood to occur when the two active ingredients are administered together, be it, for example, together in one combined unit dose form or one after the other or separately in two separate unit dose forms, and when the combined effects of the combination are greater than the algebraic sum of the two individual effects, i.e. when a more than additive efFect is achieved.

The synergistic effect can be shown experimentally, e.g. by telemetering, as follows:

For the present experiments, spontaneously hypertensive rats (SHR) are used which are 22 to 25 weeks old. Such rats are available from Taconic Farms, Germantown, New York (Tac:N(SHR)fBR). A radiotelemetric device is implanted in the lower abdominal aorta of all test animals at least one month before the experiments. The radio transmitter is fastened to the inner abdominal muscle with a silk seam. The cardiovascular parameters are continuously llansrr,iLled via the radio llansnliller, allowing data to be collected without disturbing the animals in their cages. The animals are kept in their cages at controlled temperature and allllospheric humidity and at a 12-hourly alternation of light and darkness. Thebody weights are measured at weekly intervals. Usually groups of five rats are formed. One group of animals receives only valsartan; another group receives only benazepril; a further group receives a combination of valsartan and ben~e~lil; the fourth group receives a col"l inalion of valsartan and benazeprilwhich is differently dosed; and a last group, receiving only the vehicle (0.15 NNaOH), is used as control group. Minipumps are used for continuous subcutaneous drug delivery over a 14 day interval. In these experiments, the mean arterial blood pressure and the heart beat are checked by means of a computerised data del~c:tion system (Data Sciences Inter., Inc.). The mean arterial blood pressure and the heart beat are measured every 10 minutes for 10 seconds and recorded. The values for each rat are reported as mean values over 24 hours and contain 144 data points per day. The base line for the blood pressure is determined as the average from three consecutive days before the minipump is implanted. The values during the administration of the active ingredients are 24 hour mean values. On the 1 4th day the minipumps are removed and observation of the effects is continued for 7 days after the ad",;"i~L,dlion of the active ingredients is discontinued.

These studies show that the non-combined administration of 1.5 mg/kg/day of benazepril and valsartan results in a lowering of the blood pressure of about 20mm Hg. In contrast, the combined adl"il,i~lrdlion of 1.5 mg/kg/day of ben~epril and 1.5 mg/kg/day of valsartan results in a potential lowering of the blood pressure of about 50 mg Hg. In addition, a prolonged constant duration of efficacy of up to 16 hours and a reduced, but still significant, duration of efficacy of at least up to 21 hours is achieved.

W O96t31234 PCTAEP96/01440 Additional experiments carried out with spontaneously hypertensive rats using radiotelemetry evaluating chronic effects on mean arterial blood pressure show following results:

Compound Dose AUC SEM
[mg/k~/day][mmH~l ben~epril 0.5 (N=7) - 64 6 0.75 (N=6) -136 11 1.0 (N=7) -244 30 1.5 (N=5) -213 28 3.0 (N=7) -341 20 10.0 (N=7) -581 18 valsartan 0.6 (N=7) - 62 16 0.75 (N=7) -107 6 1.0 (N=7) -115 19 1.5 (N=6) -195 8 3.0 (N=7) -226 21 10.0 (N=7) -425 38 benazepril/ 0.5 (N=6) -221 21 valsartan 0.75 (N=6) -329 20 1.0 (N=5) -470 31 1.5 (N=5) -609 23 0.15N (N=6) 1 11 NaOH (N=7) 10 9 vehicle (N=6) -23 16 (N=7) 4 13 (N=4) -11 14 1 N (N=7) -61 16 J NaHC03 [AUC = area under the curve (mmHg) since all values are recorded over 14 days, days (time) are factored out]
[SEM = standard error of means]

These results clearly underline that the AUC values, for example, of 1 mg/kg/dayfor the combination of benazepril and valsartan is dramatically higher than the additive values of 0.5 mg/kg/day of both ben~epril and valsartan.
Correspondingly, the same effect can be taken from other values.

In the remnant kidney model in the rat, the combination of valsartan and ben~epril proves to be more renal protective than either individual therapy. This model involves removal of the right kidney and ligation of 2-3 branches of the left renal artery effectively resulting in 1/6 functional renal mass. Marked proteinuria, loss of tubular electrolyte reabsorptive capacity and dldll,dlic elevations in systolic blood pressure ensues. Drug(s) are a.l",i~ rad sl Ihcut~rleously (via osmotic minipump) one week following surgery at which time the animals are in progressive, chronic renal failure. The animals remain on treatment for 6 weeks. The con,bindlion of valsartan + benazepril (Val+Bz) is given at doses of 1.0 mg/kg/day and 3.0 mg/kg/day of each agent. Individually, bena~april or valsartan at these doses are without effect or slightly improve renal function compared to vehicle treated animals. Val+Bz almost normalizes systolic blood pressure to pre-ablation levels, reduces proteinuria and greatly improves tubular function (as indicated by changes in the fractional excretions of sodium).

Likewise, a synergistic effect of a combination of valsartan and bena~ep, il in congestive heart failure can be manifested, for ~,cdmple, in an animal model in which congestive heart failure can be induced by atrial pacing. Chronic rapid heart pacing in the pig is a well-accepted model of congestive heart failure. A dose of bend~aprilate (0.15 mg/kglday) or valsartan (2.4 mg/kg/day) is selected to block the Ang I and Ang ll pressure response by 50 % without altering resting blood pressure. For the combination treatment (bena~eprildlt :/valsartan 0.04/2.4 mg/kglday), it is necessary to reduce the dose of ben~aprildla from monotherapy in order to prevent a significant fall in resting blood pressure. For comparative purposes, age matched pigs undergo chronic pacing without treatment as well as sham controls. Following 21 days of concomitant treatment and pacing tachycardia, terminal studies are performed in which left ventricular (LV) function and geometry are performed, neurohormonal profiles, isolated myocyte contractile function, adrenergic response and electrophysiology are examined. Chronic rapid pacing and O96/31234 PCT~EP96/01440 concomitant ACE inhibition reduce the LV and diastolic dimension, significantly improve LV
pump function and reduce the levels of circulating catecholamines. Ang ll receptor blockade with valsartan improves cardiac output and decreases pulmonary and systemic vascular lesi~lence. In contrast, combined bena~epril~Le and valsartan significantly provide further beneficial effects on LV geometry, function and neurohormonal activation including endothelin plasma levels Moreover, such a combination reduces LV wall stress andpulmonary and vascular resistance, important indices of myocardial oxygen consumption and LV afterload, to a greater degree than that of ACE inhibition alone. There is also an enhanced myocytes ,~ adrenergic and calcium response when compared to monotherapy with benazeprilate.

The available results indicate an unexpected beneficial effect of such a combination on blood pressure, renal blood flow and in congestive heart failure. The existence of alternative pathways responsible for the production of Ang ll in the tissues may limit the effectiveness of ACE inhibitor treatment. On the other hand, ACE i"hibilion through an effect on bradykinin degradation, improved endothelium dependent vascular reactivity. The combination of ACE inhibition and Ang ll antagonism therefore leads to a more complete blockade of the RAS and of the counter-regulatory mechanism mediated by Ang ll itself.
Accordingly, the reduction of the dosing and therefore of the probability of side-effects is also expected. This may be of importance in situations where renal function is extremely renin dependent.

It is the object of this invention to provide a pharmaceutical combination composition for the treatment of hypertension, congestive heart failure and renal failure, which composition comprises (1 ) the ACE-inhibitor benazepril or bena~eprilat or a pharmaceutically accepLable salt thereof and (2) the AT1-antagonists valsartan or a pharmaceutically acceptable salt thereof. In this composition, components (1 ) and (2) can be present and administered together, one after the other or separately in one combined unit dose form or in two separate unit dose forms.

Said pharmaceutical compositions are those for enteral, such as oral, and also rectal or parenteral administration to warm-blooded animals, the pharmacologicalactive ingredient being present on its own or together with the usual pharmaceutical excipients. The pharmaceutical compositions contain, for example, from about 0.1 % to 100 %, preferably from about 1 % to about 80 %, W O96/31234 PCT~EP96/01440 of the active ingredient. Pharmaceutical compositions for enteral or parenteral and also for ocular administration are typically those in unit dose forms, such as dragées, tablets, capsules or suppositories and also ampoules. These are prepared in a manner known per se, for example by means of conventional mixing, granulating, sugar-coating, dissolving or Iyophilising methods.
Accordingly, pharmaceutical compositions for oral use can be obtained by combining the active ingredient with solid carriers, if desired granulating a mixture obtained, and processing the mixture or granules, if desired or necess~ry after the addition of suitable excipients, to give tablets or dragée cores.

Suitable carriers are preferably fillers, typically sugars, such as lactose, saccha-rose, mannitol or sorbitol, cellulose compositions and/or calcium phosphates, e.g.
tricalcium phosphate or calciumhydrogen phosphate, furthermore binders, such as starch paste, typically using e.g. corn starch, wheat starch, rice starch or potato starch, gelatin, tragacanth gum, methylcellulose and/or polyvinyl-pyrrolidone and, if desired, disintegrants, such as the above-mentioned starches, furthermore carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, typically sodium alginate. Excipients are primarily flowregulators and lubricants, typically silica gel, talcum, stearic acid or salts thereof, typically magnesium stearate or calcium stearate, and/or polyethylene glycol.
Dragée cores are provided with suit~'E coatings which, if desired, are resistantto gastric juice, using, inter alia, concentrated sugar solutions which optionally contain gum arabic, talcum, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, coating solutions in suitable organic solvents or solvent mixtures or, for the preparation of gastric juice-resistant coatings, solutions of suitable cellulose compositions, typically acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate. Colourants or pigments may be added to the tablets or dragée coatings, for example to identify or indicate different doses of active ingredient.

Other pharmaceutical compositions for oral administration are dry-filled gelatincapsules as well as soft closed capsules made of gelatin and a pl~ticiser, such as glycerol or sorbitol. The dry-filled capsules may contain the active ingredient in the form of granules, typically in admixture with fillers, such as lactose, binders, such as starches, and/or lubricants, such as talcum or magnesium stearate. In soft capsules, the active ingredient is preferably dissolved ~! suspended in w o 96r31234 PCTAEPg6~01440 suitable liquids, such as fatty oils, paraffin oil or liquid polyethylene glycols, and stabilisers can also be added.

Suitable pharmaceutical compositions for rectal adr,l;~ lrdlion are typically suppositories consisting of a combination of the active ingredient with a su,uposilory base. Suitable suppository bases are, for example, natural or synthetic triglycerides, paraffin hydrocarbons and higher alkanols. Furthermore,gelatin rectal capsules containing a combination of the active ingredient with abase substance may also be used. Suitable base substances are, for example, liquid triglycerides, polyethylene glycols or paraffin hydrocarbons.

Suitable compositions for parenteral administration are primarily aqueous solutions of an active ingredient in water-soluble form, typically a water-soluble salt, and also suspensions of the active ingredient, such as appropriate oily injection suspensions, using suitable lipophilic solvents or vehicles, typically fatty oils, e.g. sesame oil, or synthetic fatty acid esters, typically ethyl oleate ortriglycerides, or aqueous injection suspensions containing viscosity-increasing substances, e.g. sodium carboxymethylcellulose, sorbitol and/or dextran and, optionally, also stabilisers.

It is prefer,ed to use unit dose forms that can be used for oral administration,typically tablets or capsules.

The dose of the active ingredient can depend on various factors, e.g. mode of application, species of warm-blooded animal, age and/or individual state. The estimated normal dose for oral admini:jl,dlion to a patient weighing about 75 kg is an approximate dose of the active ingredient component (1 ) [benazepril or a pharmaceutically accepldble salt therof~ of about 5 mg to about 40 mg and of theactive ingredient component (2) ~valsartan or a pharm~ceutic~lly ~ccept~'e salt thereof~ of about 20 mg to about 160 mg, preferably once or twice a day.

The weight ratio of the active ingredient component (1 ) to the active ingredient component (2) can be, for example, about 1 to 8 and also 1 to 4 or 1 to 2.

The novel combination compositions can comprise as active ingredient component (1) preferably about 10 mg to about 40 mg, more preferably 10 mg to about 20 mg and, most preferably, 10 mg.
i The novel combination compositions can comprise as active ingredient component (2) preferably about 20 mg to about 80 mg, more preferably about 40 mg to about 80 and, most preferably, about 40 mg or 80 mg.

In a pre~e"ed embodiment of this invention pharmaceutically acceptable combination compositions are used consisting of benazepril monohydrochloride and valsartan in a unit dose form. The amount of ACE-inhibitor therein is preferably 10 mg and the amount of AT1-antagonist is preferably 40 mg or 80 mg.

In the compositions of this invention the active ingredient components (1) and (2) can be obtained together, one after the other or separately in one combined unitdose form or in two separate unit dose forms. They are preferably obtained together in one combined unit dose form.

The novel pharmaceutical combination can be used for a method for the treatment of hypertension and congestive heart failure.

The method for the treatment of hypertension, congestive heart failure and renalfailure comprises administering to a patient in need of such treatment a corresponding pharmaceutical combination composition according to this invention, comprising (1) the ACE-inhibitor benazepril or benazeprilat or a pharmaceutically acceptable salt thereof and (2) the AT1-antagonists valsartan or a pharmaceutically ~ccept~hle salt thereof..

This invention also relates to the preparation of the novel pharmaceutical combination compositions.

Claims (13)

What is claimed is
1. A pharmaceutical combination composition for the treatment of hypertension, congestive heart failure and renal failure, comprising (1) the ACE-inhibitor benazepril of formula or benazeprilat of formula or a pharmaceutically acceptable salt thereof, and (2) the AT1-antagonist valsartan of formula or a pharmaceutically acceptable salt thereof.
2. A composition according to claim 1, wherein the active ingredient component (1) is benazepril monohydrochloride and the active ingredient component (2) is valsartan.
3. A composition according to either claim 1 or claim 2, comprising about 5 mg to about 40 mg of the active ingredient component (1).
4. A composition according to claim 3, comprising about 10 mg to about 40 mg of the active ingredient component (1).
5. A composition according to claim 3, comprising about 10 mg or about 20 mg of the active ingredient component (1).
6. A composition according to claim 3, comprising abount 10 mg of the active ingredient component (1).
7. A composition according to any one of claims 1-6, comprising about 20 mg to about 160 mg of the active ingredient component (2).
8. A composition according to claim 7, comprising about 20 mg to about 80 mg of the active ingredient component (2).
9. A composition according to claim 7, comprising about 40 mg or about 80 mg of the active ingredient component (2).
10. A composition according to any one of claims 1-9, comprising about 10 mg of the active ingredient component (2) and about 40 mg or about 80 mg of the active ingredient component (1).
11. A composition according to claim 1, wherein components (1) and (2) are present together, one after the other or separately in one combined or in two separate unit dose forms.
12. A method for the treatment of hypertension, congestive heart failure and renal failure which comprises administering to a patient in need of such treatment a combination of (1) the ACE-inhibitor benazepril of formula or benazeprilat of formula or a pharmaceutically acceptable salt thereof and (2) the AT1-antagonist valsartan of formula or a pharmaceutically acceptable salt thereof.
13. A method according to claim 12, wherein components (1) and (2) are administered together, one after the other or separately in one combined or in two separate unit dose forms.
CA002214143A 1995-04-07 1996-04-02 Combination compositions containing benazepril or benazeprilat and valsartan Abandoned CA2214143A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1012/95 1995-04-07
CH101295 1995-04-07

Publications (1)

Publication Number Publication Date
CA2214143A1 true CA2214143A1 (en) 1996-10-10

Family

ID=4200393

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002214143A Abandoned CA2214143A1 (en) 1995-04-07 1996-04-02 Combination compositions containing benazepril or benazeprilat and valsartan

Country Status (15)

Country Link
EP (1) EP0820302A1 (en)
JP (1) JPH11503139A (en)
KR (1) KR19980703647A (en)
CN (1) CN1181019A (en)
AU (1) AU5399096A (en)
BR (1) BR9604818A (en)
CA (1) CA2214143A1 (en)
CZ (1) CZ313897A3 (en)
HU (1) HUP9801593A2 (en)
MX (1) MX9707683A (en)
NO (1) NO974400D0 (en)
PL (1) PL322529A1 (en)
SK (1) SK133897A3 (en)
TR (1) TR199701121T1 (en)
WO (1) WO1996031234A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2224451A1 (en) * 1995-06-30 1997-01-23 Merck & Co., Inc. Method of treating renal disease using an ace inhibitor and an aii antagonist
CN101011390A (en) 1999-01-26 2007-08-08 诺瓦提斯公司 Use of angiotensin II receptor antagonists for treating acute myocardial infarction
HUP0400475A3 (en) * 2000-04-12 2006-02-28 Novartis Ag Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof
US20030207930A1 (en) * 2000-07-19 2003-11-06 Erwin Marti Valsartan salts
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
EA200300224A1 (en) * 2000-08-22 2003-08-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг PHARMACEUTICAL COMBINATION OF ANTAGONISTS OF ANGIOTENZINE II AND ACE INHIBITORS
PL362252A1 (en) * 2000-12-18 2004-10-18 Novartis Ag Therapeutic combination of amlodipine and benazepril
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
CN100377744C (en) * 2002-07-05 2008-04-02 安徽省生物医学研究所 Compound medicine for predicting ACEI pressure reducing medicine effect
EP1578360A4 (en) * 2002-08-28 2009-10-21 Curis Inc Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CN101869710A (en) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 Antihypertensive medical composite
MX346039B (en) 2009-05-20 2017-03-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical oral telmisartan solution.
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR20160107344A (en) * 2014-01-31 2016-09-13 얀센 파마슈티카 엔.브이. Methods for the treatment and prevention of renal disorders and fatty liver disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU653724B2 (en) * 1990-05-11 1994-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists

Also Published As

Publication number Publication date
MX9707683A (en) 1997-12-31
JPH11503139A (en) 1999-03-23
KR19980703647A (en) 1998-12-05
NO974400L (en) 1997-09-23
HUP9801593A2 (en) 1999-01-28
NO974400D0 (en) 1997-09-23
BR9604818A (en) 1998-06-09
WO1996031234A1 (en) 1996-10-10
EP0820302A1 (en) 1998-01-28
TR199701121T1 (en) 1998-03-21
PL322529A1 (en) 1998-02-02
CZ313897A3 (en) 1998-01-14
CN1181019A (en) 1998-05-06
SK133897A3 (en) 1998-02-04
AU5399096A (en) 1996-10-23

Similar Documents

Publication Publication Date Title
JP6373931B2 (en) Synergistic combination comprising a renin inhibitor for cardiovascular disease
EP1467728B1 (en) Pharmaceutical compositions comprising valsartan and nep inhibitors
RU2316318C2 (en) Pharmaceutical composition including renin inhibitor, calcium channel blocker and diuretic
US8404744B2 (en) Methods of treatment and pharmaceutical composition
CA2214143A1 (en) Combination compositions containing benazepril or benazeprilat and valsartan
JP2005532330A5 (en)
WO2007106708A2 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
Morganti et al. Aliskiren: the first direct renin inhibitor available for clinical use
EA009983B1 (en) Medicine for prevention of and treatment for arteriosclerosis and hypertension
US20040259925A1 (en) Pharmaceutical compositions and methds for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
EP0641218B1 (en) Use of angiotensin antagonist (at1) for reducing post myocardial infarct mobidity and mortality
CA2513281C (en) Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
EP1146872B1 (en) Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
US6767905B2 (en) Use of angiotensin II receptor antagonists for treating acute myocardial infarction
KR20230006884A (en) Pharmaceutical Combinations Comprising Brain Aminopeptidase A Inhibitors, Diuretics, and Blockers of the Systemic Renin-Angiotensin System
Waeber et al. Antihypertensive Agents: Mechanisms of Drug Action
ZA200503809B (en) Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
AU2007237280A1 (en) Pharmaceutical combination of Angiotensin II antagonists and Angiotensin I converting enzyme inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued